The 62nd American Society of Hematology (ASH) Annual Meeting and Exposition will take place virtually from December 5 through 8, 2020.
ASH 2020 is a meeting for physicians, nurses, and researchers who specialize in hematological disorders. The plenary program will concentrate on sickle cell disease, hematologic malignancies, mechanisms that lead to therapy resistance or disease progression, and disparities in treatment and outcomes.
New research will be presented across a variety of session types, including general sessions, oral and poster sessions, a scientific program, education programs, and special-interest sessions.
Selected sessions of interest will touch on disparities in health care, genome editing and cellular therapies, practice-changing clinical trials, and hematologic aspects of the coronavirus disease 2019 (COVID-19).
Cancer Therapy Advisor’s coverage will provide an overview of the most important and practically relevant blood disease research and news being released at the meeting. Coverage of data readouts from pivotal trials are expected, including presentations on the findings from ASCEMBL, Ro-CHOP, ZUMA-5, ZUMA-12, QUAZAR AML-001, CAPTIVATE, LUMMICAR-2, TRANSCEND-NHL-001, CLL14, KEYNOTE-204, TRANSCEND-CLL-004, and TOURMALINE-MM2.
In addition, the COVID-19–focused sessions will discuss the use of convalescent plasma in patients with hematological malignancies; using allogeneic, off-the-shelf, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific T cells to treat high-risk patients with COVID-19; results of the Ecovidehe Multicenter Study; and high false negative rates that have been seen in some patients. National Institute of Allergy and Infectious Diseases Director Anthony S. Fauci, MD, will discuss the most current information about the coronavirus pandemic and the effects the SARS-CoV-2 infection has had on hematologic disorders.